Treating Helicobacter pylori infection in the face of growing antibiotic resistance

Rev Esp Enferm Dig. 2019 Sep;111(9):653-654. doi: 10.17235/reed.2019.6575/2019.

Abstract

Helicobacter pylori eradication cures most peptic ulcers and non-atrophic chronic gastritis, and may potentially prevent over 70% of gastric cancers. In the late 1980s, shortly after the discovery of H. pylori, eradication therapy was established based on the use of two antibiotics (amoxicillin and clarithromycin) and one proton-pump inhibitor for 7 or 10 days (OCA7, OCA10). This therapy, recommended during the first Maastricht Consensus Conference, obtained eradication rates above 90%, and was equally effective everywhere around the world. However, over time, H. pylori has developed resistance to several antibiotics.

Publication types

  • Editorial
  • Comment

MeSH terms

  • Amoxicillin
  • Anti-Bacterial Agents
  • Clarithromycin
  • Drug Resistance, Microbial
  • Helicobacter Infections*
  • Helicobacter pylori*
  • Humans
  • Proton Pump Inhibitors

Substances

  • Anti-Bacterial Agents
  • Proton Pump Inhibitors
  • Amoxicillin
  • Clarithromycin